CYP26A1 and acute promyelocytic leukemia: In addition, synthetic retinoids that are resistant to CYP26-mediated degradation, such as tamibarotene (Sy1425) and IRX195183, were also able to bypass the stromal biochemical barrier and differentiate APL and non-APL leukemia cells in preclinical and clinical settings [89,112,113].